It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Sustained drug delivery strategies have many potential benefits for treating a range of diseases, particularly chronic diseases that require treatment for years. For many chronic ocular diseases, patient adherence to eye drop dosing regimens and the need for frequent intraocular injections are significant barriers to effective disease management. Here, we utilize peptide engineering to impart melanin binding properties to peptide-drug conjugates to act as a sustained-release depot in the eye. We develop a super learning-based methodology to engineer multifunctional peptides that efficiently enter cells, bind to melanin, and have low cytotoxicity. When the lead multifunctional peptide (HR97) is conjugated to brimonidine, an intraocular pressure lowering drug that is prescribed for three times per day topical dosing, intraocular pressure reduction is observed for up to 18 days after a single intracameral injection in rabbits. Further, the cumulative intraocular pressure lowering effect increases ~17-fold compared to free brimonidine injection. Engineered multifunctional peptide-drug conjugates are a promising approach for providing sustained therapeutic delivery in the eye and beyond.
Sustained drug delivery is critical for patient adherence to chronic disease treatments. Here the authors apply machine learning to engineer multifunctional peptides with high melanin binding, high cell-penetration, and low cytotoxicity, enhancing the duration and efficacy of peptide-drug conjugates for sustained ocular delivery.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Chemical & Biomolecular Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
2 University of Maryland, College Park, Center for Bioinformatics and Computational Biology, College Park, USA (GRID:grid.164295.d) (ISNI:0000 0001 0941 7177)
3 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Department of Ophthalmology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
4 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Pharmacology and Molecular Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
5 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Biomedical Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
6 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Case Western Reserve University, Department of Biomedical Engineering, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847)
7 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA (GRID:grid.280502.d) (ISNI:0000 0000 8741 3625)
8 Johns Hopkins University School of Medicine, Department of Ophthalmology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
9 Johns Hopkins University School of Medicine, Center for Nanomedicine at the Wilmer Eye Institute, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Chemical & Biomolecular Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University School of Medicine, Department of Ophthalmology, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Pharmacology and Molecular Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Johns Hopkins University, Department of Biomedical Engineering, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA (GRID:grid.280502.d) (ISNI:0000 0000 8741 3625)